- Home
- HCC vs EXEL Comparison
HCC vs EXEL Comparison
Compare HCC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCC | EXEL |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 11.1B |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HCC | EXEL |
|---|---|---|
| Price | $89.16 | $46.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 24 |
| Target Price | ★ $74.50 | $45.18 |
| AVG Volume (30 Days) | 755.4K | ★ 2.7M |
| Earning Date | 02-12-2026 | 02-10-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | 0.67 | ★ 2.38 |
| Revenue | $1,224,320,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | $46.92 | $11.92 |
| P/E Ratio | $133.33 | ★ $19.61 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $38.00 | $31.90 |
| 52 Week High | $89.90 | $49.62 |
Technical Indicators
Market Signals| Indicator | HCC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 70.77 | 69.33 |
| Support Level | $78.00 | $40.83 |
| Resistance Level | $89.90 | $47.24 |
| Average True Range (ATR) | 3.25 | 1.24 |
| MACD | 0.37 | 0.42 |
| Stochastic Oscillator | 93.78 | 88.91 |
Price Performance
Historical ComparisonAbout HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.